Sysmex Profit Slumps but Payouts Rise as Balance Sheet Strengthens

Sysmex ( (JP:6869) ) just unveiled an update.

Sysmex reported a 1.7% decline in net sales to ¥500.0 billion for the fiscal year ended March 31, 2026, while operating profit fell sharply by 40.8% and profit attributable to owners of the parent dropped 33.9%, reflecting margin pressure and weaker profitability. Despite the earnings downturn, the company’s financial position strengthened with total assets and equity rising, cash flow from operations remaining solid, and the equity ratio improving, enabling Sysmex to raise its annual dividend to ¥38 per share, including commemorative payouts, and to project modest sales and profit growth for the next fiscal year.

The higher dividend, combined with an improved equity ratio of 71.4% and stable cash generation, signals management’s confidence in the company’s balance sheet and future earnings resilience despite current profit compression. For the year ending March 31, 2027, Sysmex forecasts a recovery in operating profit and profit before tax, alongside 7.0% net sales growth, suggesting efforts to restore margins and sustain shareholder returns even as near-term interim profits are expected to remain under pressure.

The most recent analyst rating on (JP:6869) stock is a Hold with a Yen1500.00 price target. To see the full list of analyst forecasts on Sysmex stock, see the JP:6869 Stock Forecast page.

More about Sysmex

Sysmex Corporation is a Japan-based medical device company specializing in diagnostic instruments and reagents, particularly in hematology and in-vitro diagnostics. Listed on the Tokyo Stock Exchange, the company serves hospitals and laboratories worldwide, focusing on clinical testing solutions that support healthcare delivery and disease management in key global markets.

Average Trading Volume: 4,389,826

Technical Sentiment Signal: Sell

Current Market Cap: Yen812.6B

Learn more about 6869 stock on TipRanks’ Stock Analysis page.